pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › Condition › Ophthalmology & Eye

Upcoming Ophthalmology & Eye FDA decisions & readouts

Updated ยทnext FDA decision on the calendar
PDUFA target dates and trial readouts in ophthalmology & eye, each linked to its primary source. Updated from FDA/SEC/ClinicalTrials.gov; dates can shift.
Cancer & OncologyObesity & MetabolicCNS & NeurologyImmunology & InflammationCardiovascularRare DiseaseInfectious Disease & VaccinesHematology

PDUFA decisions (1)

OTLK · 2026-07-29
bevacizumab: Age-Related Macular Degeneration

Trial readouts (24)

ANIP · Jul 2026 (est.)
Yutiq: Uveitis
OCGN · Jul 2026 (est.)
OCU410ST: Center Involved Diabetic Macular Edema
KOD · Aug 2026 (est.)
Tarcocimab Tedromer: Wet Age-related Macular Degeneration
EYPT · Aug 2026 (est.)
EYP-1901: Wet Age Related Macular Degeneration
RGNX · Aug 2026 (est.)
Ranibizumab: Neovascular Age-Related Macular Degeneration (nAMD)
VNDA · Sep 2026 (est.)
VSJ-110: Dry Eye
EYPT · Oct 2026 (est.)
EYP-1901: Wet Age Related Macular Degeneration
ANNX · Oct 2026 (est.)
Tanruprubart: Geographic Atrophy
KPRX · Nov 2026 (est.)
KIO-104: Macular Edema
SKYE · Nov 2026 (est.)
SBI-100 Ophthalmic Emulsion,: Obesity
FDMT · 2026-H2
4D-150 IVT: Macular Neovascularization Secondary to Age-Related Macular Degeneration
OCUL · Jan 2027 (est.)
Otx-Tki: Neovascular Age-related Macular Degeneration
KOD · Feb 2027 (est.)
KSI-101: Macular Edema Secondary to Inflammation
SGP · Feb 2027 (est.)
Bimatoprost Implant System: Glaucoma
FDMT · Mar 2027 (est.)
4D-150 IVT: Neovascular (Wet) Age-Related Macular Degeneration
KOD · Apr 2027 (est.)
KSI-101: Macular Edema Secondary to Inflammation
FDMT · Jun 2027 (est.)
4D-150 IVT: Macular Neovascularization Secondary to Age-Related Macular Degeneration
BLTE · Jun 2027 (est.)
Tinlarebant: Geographic Atrophy
ALVO · Jul 2027 (est.)
Eylea Hd: Diabetic Macular Edema
AMGN · Jul 2027 (est.)
ABP 938: Neovascular Age-related Macular Degeneration
EYPT · Oct 2027 (est.)
EYP-1901: Diabetic Macular Edema
REGN · Nov 2027 (est.)
Cemdisiran: Age-related Macular Degeneration (AMD)
RGNX · Dec 2027 (est.)
Ranibizumab: Diabetic Macular Edema
OTLK · Dec 2027 (est.)
bevacizumab: Age-Related Macular Degeneration
We don't show an approval percentage for these ophthalmology & eye catalysts. Here's why.